Cyclacel
About Cyclacel Pharmaceuticals

Management Team

Spiro Rombotis

President and Chief Executive Officer

Mr. Rombotis joined Cyclacel as its first CEO in 1997 and has 30 years of experience with biopharmaceutical companies. He was previously Vice President, International Operations and Business Development; Managing Director, Europe; and Representative Director, Japanese joint venture, at The Liposome Company, subsequently acquired by Elan. He held various executive roles at Bristol-Myers Squibb Company, most recently as Vice President, Pharmaceuticals Central and Eastern Europe. He was Head of European Marketing and Sales, Head of Corporate Development and one of the first employees of Centocor, subsequently acquired by Johnson & Johnson, and worked in Business Development at Novartis AG. He holds a BA from Williams College and an MBA and Master's degree in Hospital Management with honors, from the Kellogg Graduate School of Management, where he serves on the Kellogg Biotech Advisory Board. He also serves on the Board of Trustees of BioNJ, the biotechnology trade group in New Jersey.

Paul McBarron

Executive Vice President, Finance and Chief Operating Officer and Secretary

Mr. McBarron joined Cyclacel Pharmaceuticals in January 2002 and has over 20 years of experience with pharmaceutical and biotechnology companies. He has served as a financial executive at Sterling Drug, Sanofi-Winthrop and SmithKline Beecham and most recently, from 1996 to 2001, as a senior member of the finance team at Shire Pharmaceuticals plc, where he held the positions of Director of Corporate Finance and Group Financial Controller. He joined Shire when it was an emerging public company. He qualified as a chartered accountant with Ernst & Young and serves on the Life Sciences Industry Advisory Board for the Scottish Government.

Judy Chiao, M.D.

Vice President, Clinical Development and Regulatory Affairs

Dr. Chiao joined Cyclacel Pharmaceuticals in December 2004. From September 2002 to December 2004, she was at Aton Pharma, Inc., a wholly owned subsidiary of Merck & Co. Inc., most recently as Vice President, Oncology Clinical Research and Development. Prior to Aton's acquisition by Merck, she was responsible for leading the clinical development of Zolinza, a histone deacetylase inhibitor, for hematologic and solid tumor indications. From July 2000 to December 2001, Dr. Chiao was a Senior Medical Reviewer, Division of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, where she was the agency's primary reviewer for a range of oncology drugs and regulatory subjects. She also presented the FDA's views in several New Drug Application reviews at Oncology Drug Advisory Committees. Dr. Chiao earned her Bachelor of Science in Chemistry (summa cum laude) at Columbia University, New York, and received her medical degree from Harvard Medical School. Her internship and residency in internal medicine was carried out at Columbia-Presbyterian Medical Center, New York and she held a Research Fellowship in Molecular Pharmacology at Sloan Kettering Institute for Cancer Research and a Clinical Fellowship in Hematology/Oncology at Memorial Sloan Kettering Cancer Center both in New York City. She has also been a member of a number of FDA-related working groups and has also been a Core Member of the Pharsight-FDA Cooperative Research and Development Agreement (CRADA) on clinical trial simulation and population pharmacokinetic analysis software for drug development.

Amartya Basu, Ph.D., MBA

Senior Director, Project Management and Business Development

Dr. Basu joined Cyclacel Pharmaceuticals in September 2018. He brings 20+ years of R&D, project/program management and business development experience to Cyclacel. He held various leadership roles in academia, biotech and pharmaceutical companies. Prior to joining Cyclacel, Dr. Basu served as a principal consultant to CMK Select and helped Celgene in the lifecycle management of Istodax, a PTCL/CTCL drug. At Hoffmann La Roche, he was involved in managing various oncology and non-oncology drugs in global development, and served in various due diligence activities, six of which have been integrated into Roche portfolio. He started his industry career at Enzon Pharmaceuticals, Inc. where he led a team of scientists through cutting-edge research and development activities in protein therapeutics and, secured break-through publications and patents. He received his Executive MBA degree from Rutgers University and earned his Ph.D. in Biochemistry from the University of Medicine and Dentistry of New Jersey (currently under Rutgers University).

 

Research & Development